Smith & Nephew’s (SNN) Neutral Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their neutral rating on shares of Smith & Nephew (NYSE:SNN) in a research report released on Thursday morning, The Fly reports.

A number of other equities research analysts have also issued reports on SNN. Morgan Stanley reiterated an overweight rating on shares of Smith & Nephew in a report on Thursday. Berenberg Bank reiterated a buy rating on shares of Smith & Nephew in a report on Friday, July 10th. Exane BNP Paribas lowered shares of Smith & Nephew from a neutral rating to an underperform rating in a report on Friday, June 5th. BofA Securities upgraded shares of Smith & Nephew from a neutral rating to a buy rating in a report on Wednesday. Finally, Zacks Investment Research upgraded shares of Smith & Nephew from a sell rating to a hold rating in a report on Tuesday, June 2nd. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $48.00.

Shares of SNN stock opened at $39.81 on Thursday. The firm’s 50 day moving average price is $40.12 and its 200-day moving average price is $41.58. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.03 and a current ratio of 2.18. Smith & Nephew has a one year low of $26.07 and a one year high of $52.26.

The company also recently disclosed a Semi-Annual dividend, which will be paid on Wednesday, October 28th. Shareholders of record on Friday, October 2nd will be given a $0.278 dividend. This represents a dividend yield of 1.8%. The ex-dividend date of this dividend is Thursday, October 1st. Smith & Nephew’s dividend payout ratio is presently 44.12%.

Several large investors have recently made changes to their positions in SNN. FMR LLC increased its position in shares of Smith & Nephew by 640.8% in the 1st quarter. FMR LLC now owns 1,341,034 shares of the medical equipment provider’s stock valued at $53,788,000 after purchasing an additional 1,160,015 shares during the last quarter. Credit Suisse AG grew its position in shares of Smith & Nephew by 136.2% in the 4th quarter. Credit Suisse AG now owns 17,000 shares of the medical equipment provider’s stock valued at $817,000 after buying an additional 9,804 shares during the last quarter. Guggenheim Capital LLC grew its position in shares of Smith & Nephew by 29.0% in the 4th quarter. Guggenheim Capital LLC now owns 18,558 shares of the medical equipment provider’s stock valued at $892,000 after buying an additional 4,174 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Smith & Nephew by 8.0% in the 4th quarter. Bank of New York Mellon Corp now owns 129,436 shares of the medical equipment provider’s stock valued at $6,222,000 after buying an additional 9,625 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Smith & Nephew in the 4th quarter valued at $333,000. 9.40% of the stock is currently owned by institutional investors.

About Smith & Nephew

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Featured Article: Debt-To-Equity Ratio

The Fly

Analyst Recommendations for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.